18 results about "Nephrotic syndrome" patented technology

The present invention provides an adeno-associated virus (AAV) vector gene therapy for use in treating a monogenic form of nephrotic syndrome, wherein the AAV vector comprises a NS-associated transgene and minimal nephrin promoter NPHIS1 or podocin promoter NPHIS2.

This invention provides a kit for detecting anti-peroxidase-1-IgG antibodies, comprising the antigen protein peroxiredoxin-1 (peroxidase-1), a solid-phase carrier, labeled antibody, antigen dilution buffer, sample dilution buffer, antibody dilution buffer, substrate chromogenic agent, washing buffer, standards, positive control, and negative control. This kit utilizes an indirect reaction principle combined with magnetic microparticle chemiluminescence immunoassay to detect anti-peroxidase-1-IgG antibodies in the serum of the test sample. This invention is the first to identify autoantibodies against the target antigen peroxidase-1 in the serum of patients with autoimmune nephrotic syndrome. The provided kit provides a basis for domestic and international research on the molecular mechanisms and clinical diagnosis and treatment of autoimmune nephrotic syndrome related to peroxidase-1 and peroxidase-1-IgG autoantibodies.

1. Name of the product in this design: Treatment cart (for rehabilitation treatment of children with nephrotic syndrome). 2. Purpose of this design: For use in the rehabilitation treatment of sick children. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: 3D view 1.

The present invention provides an adeno-associated virus (AAV) vector gene therapy for use in treating a monogenic form of nephrotic syndrome, wherein the AAV vector comprises a NS-associated transgene and minimal nephrin promoter NPHS1 or podocin promoter NPHS2.

The invention relates to an anti-CD45RO monoclonal antibody and application thereof in preparation of drugs for treating autoimmune diseases, the anti-CD45RO monoclonal antibody comprises an antibody heavy chain variable region and / or an antibody light chain variable region: a) the antibody heavy chain variable region comprises three complementary determining regions: CDR1, CDR2 and CDR3; and b) an antibody light chain variable region, wherein the antibody light chain variable region comprises complementarity determining regions: L-CDR1, L-CDR2 and L-CDR3. The invention also comprises application of the anti-CD45RO monoclonal antibody in preparation of drugs for treating immune diseases. The monoclonal antibody aiming at the CD45RO can specifically recognize and combine CD45RO molecules on the surfaces of the memory T cells, so that the activation and function of the memory T cells are blocked, and the inflammatory response of immune diseases is reduced by reducing the activity of the memory T cells, so that the symptoms of patients are improved. The compound is expected to be used for preparing medicines for treating immune diseases such as nephrotic syndrome.

The application discloses a chemical structural formula of a biphenyl sulfonamide compound of a bis-benzimidazole, and also discloses application of the compound in preparation of a pharmaceutically acceptable salt or solvate, application of the compound and the pharmaceutically acceptable salt or solvate in preparation of a medicine for treating endothelin-dependent or angiotensin II-dependent diseases. Meanwhile, the biphenyl sulfonamide compound of the bis-benzimidazole can also be used in combination by changing substituted functional groups. The biphenyl sulfonamide compound of the bis-benzimidazole, the prepared pharmaceutically acceptable salt or solvate and the medicine prepared by the compound have pharmacological activities, and have pharmacological effects in animals including human beings, and are particularly useful in treatment or prevention of IgA nephropathy, focal segmental glomerulosclerosis, nephrotic syndrome, chronic kidney disease, diabetic nephropathy, hypertension, coronary heart disease and myocardial infarction.

The application belongs to the technical field of nephropathy diagnosis medicine or reagent, and particularly relates to application of multiple groups of metabolic markers in differential diagnosis of different pathological types of nephrotic syndrome. The multiple groups of metabolic markers for diagnosing different pathological types of nephrotic syndrome (including membranous nephropathy and minimal change nephropathy) are provided, and the existing diagnosis means cannot realize non-invasive, rapid and effective pathological type differential diagnosis of primary nephrotic syndrome. The markers include markers for diagnosing membranous nephropathy and / or markers for diagnosing minimal change nephropathy. The markers can be used for preparing differential diagnosis products of different pathological types of nephrotic syndrome, the sample of a subject is pretreated, the level of the marker in the sample is determined and analyzed, the type of nephropathy of the subject is diagnosed, and the application has important clinical application value.

Hydantoin based compounds of formula (I) useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

Provided is a use of ephrin-B as a marker for assisting in the diagnosis of nephrotic syndrome. A nephrotic syndrome testing method comprises a step for measuring the level of expression of ephrin-B in the urine of a subject. A reagent for nephrotic syndrome diagnosis includes a substance that specifically binds to ephrin-B.

The application provides a preparation method of total saponins of Radix Fritillariae Thunbergii, which comprises the following steps: adding Radix Fritillariae Thunbergii into ethanol to extract, and then concentrating under reduced pressure to obtain a crude extract; dissolving the crude extract in water, and then adsorbing the water on macroporous adsorption resin, and then eluting the macroporous adsorption resin with water and ethanol; collecting the ethanol eluate, and then concentrating under reduced pressure to obtain component 1; dissolving the component 1 in water, and then extracting with an organic solvent; and drying the water phase obtained by extraction under reduced pressure to obtain the total saponins of Radix Fritillariae Thunbergii. The application optimizes the extraction and purification method of the total saponins of Radix Fritillariae Thunbergii to a certain extent, shortens the preparation time of the total saponins, improves the content of the total saponins, and proves through experimental research that the total saponins of Radix Fritillariae Thunbergii can treat the nephrotic syndrome caused by adriamycin (ADR), improve the glomerular filtration rate, reduce the glomerular inflammation, and has a significant protective effect on the kidney.

The invention discloses a traditional Chinese medicine compound preparation for treating nephrotic syndrome and a preparation method of the traditional Chinese medicine compound preparation, and belongs to the technical field of nephrotic syndrome treatment.The synbiotic microcapsule is prepared by compatibility of traditional Chinese medicines such as safflower, scutellaria baicalensis and perilla frutescens, and the synbiotic microcapsule is prepared by embedding traditional Chinese medicine extracts such as astragalus membranaceus and lily with lactobacillus acidophilus and bifidobacterium; and the wall material is prepared from mannose grafted meadowfoam seed extract, sodium alginate and fucoidin sulfate. The synbiotics microcapsule utilizes a Maillard reaction modified wall material to enhance gastric acid erosion resistance, realizes intestinal targeted colonization through mannose residues, protects probiotics, directionally releases traditional Chinese medicine active components, adjusts intestinal flora balance and inhibits uremia toxin generation. The traditional Chinese medicine components such as the safflower and the scutellaria baicalensis improve kidney blood circulation, relieve inflammatory response and regulate lipid metabolism by inhibiting an NF-kappa B channel, activating an AMPK channel and the like; the components such as the Chinese yam and the Chinese wolfberry can repair the permeability of glomerular basement membrane and improve the hypoproteinemia.

This invention relates to the field of traditional Chinese medicine (TCM) technology, and particularly to the application of TCM compositions in the preparation of drugs for the prevention and treatment of nephrotic syndrome. The TCM composition of this invention includes *Sedum sarmentosum*, seaweed, oyster shell, hawthorn, *Siegesbeckia orientalis*, *Schisandra chinensis*, and *Polygonum cuspidatum*. This invention has found that this composition can significantly reduce urinary protein levels, regulate serum ALB, Cr, and BUN levels, improve renal function, and has a good therapeutic effect on nephrotic syndrome. Moreover, this TCM composition is an existing prepared Chinese medicine, safe to use, and its preparation method is simple, rapid, efficient, and easy to operate. The prepared mixtures, tablets, capsules, and micro-pellets are easy to carry and convenient to take.

The invention provides an application of glutamine in treatment of primary nephrotic syndrome and an application thereof, and particularly relates to an application of a combination of glutamine or a derivative thereof or glutamine guat acid sodium and prednisone acetate in preparation of a medicine, and the medicine is used for preventing, relieving and / or treating the primary nephrotic syndrome. According to the application disclosed by the invention, the glutamine or the derivative thereof and the prednisone acetate are combined for use, so that the negative conversion time of the primary nephrotic syndrome can be effectively shortened, the times of later recurrence and infection are reduced, the prognosis effect is improved, and a new thought is provided for preventing, relieving and / or treating the primary nephrotic syndrome.

The present invention provides an adeno-associated virus (AAV) vector gene therapy for use in treating a monogenic form of nephrotic syndrome, wherein the AAV vector comprises a NS-associated transgene and minimal nephrin promoter NPHS1 or podocin promoter NPHS2.

The application discloses a midstream urine collection and analysis device for nephrotic syndrome patients and belongs to the field of medical urine detection instruments. The device comprises a support, a midstream urine storage bin, an initial and final urine storage bin, a switching device, a floating trigger mechanism, a tension sensor, a controller, a pneumatic cylinder and a test paper clamping device integrated in the midstream urine storage bin. The floating trigger mechanism detects the initial urine volume, and the signal is transmitted through the tension sensor to control the pneumatic cylinder to drive the switching plate to slide, so that the urine flow channel is automatically switched, and the initial, midstream and final urine is stored in different bins. The test paper clamping device is divided into a test paper bearing mechanism and a pressing type test paper taking and placing mechanism. The application realizes automatic urine segmentation and collection, has high sampling standardization, reduces urine pollution and detection errors, is suitable for long-term and multiple urine routine detection of nephrotic syndrome patients, has a structure easy to clean and high automation, and is suitable for clinical popularization and use.

The invention relates to the technical field of medical information, in particular to an intelligent algorithm system for accurate diagnosis, treatment and management of the whole cycle of nephropathy. Through deep coupling of a core algorithm and in combination with two exclusive quantification formulas, transformation of nephropathy diagnosis and treatment from'experience-driven 'to'algorithm-driven' is realized, the core pain points of high early-stage missed diagnosis rate, progress pre-judgment lag, treatment scheme homogenization, inaccurate follow-up management and the like in traditional diagnosis and treatment are solved, accurate decision support is provided for clinicians, and the clinical diagnosis and treatment efficiency is improved. The method provides whole-cycle individualized diagnosis and treatment service for patients, and is suitable for diagnosis and treatment scenes of various nephropathy such as chronic kidney disease (CKD), acute kidney injury (AKI), nephrotic syndrome and the like. The core innovation of the method lies in breakthrough of algorithm modeling logic and solving process, a scientific decision-making system is constructed through an exclusive quantification formula, the industry blank of nephropathy full-cycle algorithm collaborative innovation is filled, and intelligent upgrading of diagnosis and treatment is promoted.

As a compound that can be used as a therapeutic or preventative agent for diseases involving TRPC6, such as nephrotic syndrome, membranous nephropathy, acute renal failure, sepsis, chronic renal failure, diabetic nephropathy, pulmonary hypertension, acute lung injury, heart failure, malignant tumors, and muscular dystrophy, a compound of formula (I) or a pharmaceutically acceptable salt thereof is provided (where Ar... 1 Ar 2 X 1 ~X 3 R 1 R 3 R 7 R 8 and L 1 L 2 (As defined in the instruction manual).